Orion Oyj (LON:0M2O)

Market Cap	7.81B
Revenue (ttm)	1.42B
Net Income (ttm)	273.38M
Shares Out	n/a
EPS (ttm)	1.94
PE Ratio	28.56
Forward PE	18.14
Dividend	1.41 (2.21%)
Ex-Dividend Date	Oct 15, 2025

Volume	5,023
Average Volume	28,018
Open	63.68
Previous Close	63.73
Day's Range	63.65 - 64.05
52-Week Range	42.68 - 72.00
Beta	0.30
RSI	64.93
Earnings Date	Feb 12, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 3,880
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0M2O

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.

Financial numbers in EUR